Boehringer Ingelheim and Weill Cornell Medicine will together identify new treatment approaches for chronic obstructive pulmonary disease (COPD).
The collaboration will lay the foundations to develop novel treatments that could possibly halt or even reverse the progression of the disease process.
The new, three-year collaboration combines Weill Cornell Medicine’s Department of Genetic Medicine’s understanding of chronic airway diseases and experience in the investigation of novel therapeutic concepts for airway repair with Boehringer Ingelheim’s expertise in the discovery and development of new therapies for respiratory diseases.
This is the second collaboration between Boehringer Ingelheim and Weill Cornell Medicine, following prior work in inflammatory bowel disease.
Chronic lower respiratory diseases are the third leading cause of death in the United States, and approximately 15 million Americans have been told by a healthcare provider that they have COPD. It cannot be cured and current treatment approaches focus on bronchodilation, reducing symptoms and preventing exacerbations to decelerate the downward spiral of the disease. The goal is to help patients keep as active as possible and overall, improve their quality of life.
“Our continuous search for molecular drivers of chronic obstructive airway diseases has revealed novel repair mechanisms that warrant further investigation of their potential as therapeutic approaches,” said Dr. Ronald G. Crystal, Chairman of Genetic Medicine at Weill Cornell Medicine and lead investigator in the new collaboration.
Dr. Clive R. Wood, Senior Corporate Vice President, Discovery Research at Boehringer Ingelheim, added: “The scientists at Weill Cornell Medicine and Boehringer Ingelheim will work hand in hand to translate new discoveries into drug discovery and development programs at Boehringer Ingelheim.”
Image credit: Shutterstock.com/ Matej Kastelic